Recursion Pharmaceuticals (RXRX) Long-Term Deferred Tax (2024 - 2026)
Recursion Pharmaceuticals' (RXRX) quarterly Long-Term Deferred Tax came in at $957000.0 in Q1 2026, down 52.22% YoY from $2.0 million in Q1 2025, and little changed on a QoQ basis from $957000.0 in Q4 2025.
Recursion Pharmaceuticals (RXRX) Long-Term Deferred Tax (2024 - 2026) Analysis & Trends
Recursion Pharmaceuticals (RXRX) has 3 years of Long-Term Deferred Tax data on file, last reported at $957000.0 in Q1 2026.
- Quarterly Long-Term Deferred Tax fell 52.22% year-over-year to $957000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $957000.0 (down 52.22% YoY) and the FY2025 annual result came in at $957000.0, down 50.52% from the prior year.
- Long-Term Deferred Tax was little changed at $957000.0 in Q1 2026, from $957000.0 in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $2.0 million in Q1 2025 to a low of $957000.0 in Q2 2025.
- A 3-year average of $1.3 million and a median of $957000.0 in 2025 frame the typical range for Long-Term Deferred Tax.
- Annual changes were most pronounced in 2025 — Long-Term Deferred Tax tumbled 50.52% — and 2026, when it slumped 52.22%.
- Tracing RXRX's Long-Term Deferred Tax over 3 years: stood at $1.9 million in 2024, then plunged by 50.52% to $957000.0 in 2025, then changed by 0.0% to $957000.0 in 2026.
- The last three Long-Term Deferred Tax figures came in at $957000.0 (Q1 2026), $957000.0 (Q4 2025), and $957000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Recursion Pharmaceuticals | 1.69 Bn | 1.14 Bn | -3.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 957,000.00 |
| Mar 31, 2026 | 957,000.00 |
| Dec 31, 2025 | 957,000.00 |
| Sep 30, 2025 | 957,000.00 |
| Jun 30, 2025 | 957,000.00 |
| Mar 31, 2025 | 2.00 Mn |
| Dec 31, 2024 | 1.93 Mn |